{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:06:51Z","timestamp":1784642811442,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010068","name":"Medizinische Fakult\u00e4t, Universit\u00e4t Duisburg-Essen","doi-asserted-by":"publisher","award":["IFORES"],"award-info":[{"award-number":["IFORES"]}],"id":[{"id":"10.13039\/501100010068","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014837","name":"Rudolf-Ackermann-Stiftung","doi-asserted-by":"crossref","award":["Rudolf-Ackermann-Stiftung (Stiftung f\u00fcr Klinische Infektiologie)"],"award-info":[{"award-number":["Rudolf-Ackermann-Stiftung (Stiftung f\u00fcr Klinische Infektiologie)"]}],"id":[{"id":"10.13039\/501100014837","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dysregulation of the B-cell activating factor (BAFF) system is involved in the pathogenesis of systemic lupus erythematosus (SLE). Increased serum concentrations of BAFF are related to lupus nephritis and disease activity among SLE patients. Recently, a variant of the BAFF-encoding gene, BAFF-var, was identified to be associated with autoimmune diseases, in particular SLE, and to promote the production of soluble BAFF. The present study aimed to assess the prevalence of BAFF-var in a cohort of 195 SLE patients and to analyze the association of the BAFF-var genotype (TNSF13B) with various manifestations of SLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort of 195 SLE patients from Central Europe, including 153 patients from the Swiss SLE Cohort Study and 42 patients from the University Hospital Essen, Germany, underwent genotyping for detection of BAFF-var allele.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 195 patients, 18 (9.2%) tested positive for BAFF-var variant according to the minor allele frequency of 4.6%. The presence of BAFF-var was associated with the occurrence of lupus nephritis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.038) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). Among various organ manifestations of SLE, the presence of BAFF-var was associated with the occurrence of lupus nephritis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.038; odds ratio [OR], 2.4; 95% confidence interval [CI], 0.89\u20136.34) and renal activity markers such as proteinuria and hematuria (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03; OR, 2.4; 95% CI, 0.9\u20136.4 for proteinuria;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003; OR, 3.9; 95% CI, 1.43\u201310.76 for hematuria). SLE patients carrying the BAFF-var allele exhibited increased disease activity at study entry, as determined by the physician\u2019s global assessment (PGA:\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002; OR, 4.8; 95% CI, 1.54\u201314.93) and the SLE Disease Activity Index (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012; OR, 3.5; 95% CI, 1.12\u201311.18). Consistent with that, the percentage of patients treated with immunosuppressive agents at study entry was higher among those carrying the BAFF-var allele than among those tested negative for BAFF-var (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006; OR, 3.7; 95% CI, 1.27\u201310.84).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results indicate an association between the BAFF-var genotype and increased severity of SLE. Determining the BAFF-var status of SLE patients may improve the risk stratification of patients for whom the development of lupus nephritis is more likely and thus may be helpful in the follow-up care and treatment of SLE patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-019-1623-4","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T11:03:17Z","timestamp":1574334197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-1240","authenticated-orcid":false,"given":"Justa","family":"Friebus-Kardash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marten","family":"Trendelenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Eisenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Ribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Chizzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uyen","family":"Huynh-Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Sebastian","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Dolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Hardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"1623_CR1","first-page":"414","volume":"33","author":"G Mirabelli","year":"2015","unstructured":"Mirabelli G, Cannarile F, Bruni C, Vagelli R, De Luca R, Carli L. One year in review 2015: systemic lupus erythematosus. Clin Exp Rheumatol. 2015;33:414\u201325.","journal-title":"Clin Exp Rheumatol"},{"key":"1623_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1681\/ASN.2006090992","volume":"18","author":"SM Korbet","year":"2007","unstructured":"Korbet SM, Schwartz MM, Evans J, Lewis EJ, Collaborative Study Group. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18:244\u201354.","journal-title":"J Am Soc Nephrol"},{"key":"1623_CR3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.semarthrit.2004.07.002","volume":"34","author":"Y Sherer","year":"2004","unstructured":"Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum. 2004;34:501\u201337.","journal-title":"Semin Arthritis Rheum"},{"key":"1623_CR4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMra071297","volume":"358","author":"A Rahman","year":"2008","unstructured":"Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929\u201339.","journal-title":"N Engl J Med"},{"key":"1623_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.autrev.2010.09.007","volume":"10","author":"R Gualtierotti","year":"2010","unstructured":"Gualtierotti R, Biggioggero M, Penatti AE, Meroni PL. Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2010;10:3\u20137.","journal-title":"Autoimmun Rev"},{"key":"1623_CR6","first-page":"1241","volume":"11","author":"Q Pan","year":"2019","unstructured":"Pan Q, Chen J, Guo L, Lu X, Liao S, Zhao C, et al. Mechanistic insights into environmental and genetic risk factors for systemic lupus erythematosus. Am J Transl Res. 2019;11:1241\u201354.","journal-title":"Am J Transl Res"},{"key":"1623_CR7","doi-asserted-by":"publisher","unstructured":"Kandala NB, Connock M, Grove A, Sutcliffe P, Mohiuddin S, Hartley L, et al. Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. BMJ Open. 2013;3. https:\/\/doi.org\/10.1136\/bmjopen-2013-002852.","DOI":"10.1136\/bmjopen-2013-002852"},{"key":"1623_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/PROM.S134326","volume":"10","author":"E Bangert","year":"2019","unstructured":"Bangert E, Wakani L, Merchant M, Strand V, Touma Z. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies. Patient Relat Outcome Meas. 2019;10:1\u20137.","journal-title":"Patient Relat Outcome Meas"},{"key":"1623_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","volume":"10","author":"FB Vincent","year":"2014","unstructured":"Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF\/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10:365\u201373.","journal-title":"Nat Rev Rheumatol"},{"key":"1623_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/ndt\/gfu213","volume":"30","author":"MD Sanchez-Ni\u00f1o","year":"2015","unstructured":"Sanchez-Ni\u00f1o MD, Ortiz A. That obscure object of Desire': in systemic lupus erythematosus B-cell activating factor\/B-lymphocyte stimulator is targeted both by the immune system and by physicians. Nephrol Dial Transplant. 2015;30:394\u2013400.","journal-title":"Nephrol Dial Transplant"},{"key":"1623_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/ndt\/gfx220","volume":"33","author":"J Friebus-Kardash","year":"2018","unstructured":"Friebus-Kardash J, Branco L, Ribi C, Chizzolini C, Huynh-Do U, Dubler D, Roux-Lombard P, Dolff S, Kribben A, Eisenberger U, Trendelenburg M. Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus. Nephrol Dial Transplant. 2018;33:54\u201364.","journal-title":"Nephrol Dial Transplant"},{"key":"1623_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1177\/0961203313496302","volume":"22","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus. 2013;22:873\u201384.","journal-title":"Lupus"},{"key":"1623_CR13","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/art.23678","volume":"58","author":"M Petri","year":"2008","unstructured":"Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58:2453\u20139.","journal-title":"Arthritis Rheum"},{"key":"1623_CR14","first-page":"491","volume":"16","author":"D Elbirt","year":"2014","unstructured":"Elbirt D, Asher I, Mahlab-Guri K, Bezalel-Rosenberg S, Edelstein V, Sthoeger Z. BLyS levels in sera of patients with systemic lupus erythematosus: clinical and serological correlation. Isr Med Assoc J. 2014;16:491\u20136.","journal-title":"Isr Med Assoc J"},{"key":"1623_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair HA, Duggan ST. Belimumab: a review in systemic lupus erythematosus. Drugs. 2018;78:355\u201366.","journal-title":"Drugs"},{"key":"1623_CR16","doi-asserted-by":"publisher","first-page":"e025687","DOI":"10.1136\/bmjopen-2018-025687","volume":"9","author":"YKO Teng","year":"2019","unstructured":"Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open. 2019;9:e025687.","journal-title":"BMJ Open"},{"key":"1623_CR17","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","volume":"376","author":"M Steri","year":"2017","unstructured":"Steri M, Orr\u00f9 V, Idda ML, et al. Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med. 2017;376:1615\u201326.","journal-title":"N Engl J Med"},{"key":"1623_CR18","doi-asserted-by":"publisher","first-page":"12040","DOI":"10.1093\/nar\/gky866","volume":"46","author":"ML Idda","year":"2018","unstructured":"Idda ML, Lodde V, McClusky WG, et al. Cooperative translational control of polymorphic BAFF by NF90 and miR-15a. Nucleic Acids Res. 2018;46:12040\u201351.","journal-title":"Nucleic Acids Res"},{"key":"1623_CR19","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1038\/s41598-018-26573-4","volume":"8","author":"D Gonz\u00e1lez-Serna","year":"2018","unstructured":"Gonz\u00e1lez-Serna D, Ortiz-Fern\u00e1ndez L, Vargas S, et al. Association of a rare variant of the TNFSF13B gene with susceptibility to rheumatoid arthritis and systemic lupus erythematosus. Sci Rep. 2018;8:8195.","journal-title":"Sci Rep"},{"key":"1623_CR20","first-page":"S-85","volume":"32","author":"I Castrej\u00f3n","year":"2014","unstructured":"Castrej\u00f3n I, Tani C, Jolly M, Huang A, Mosca M. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. Clin Exp Rheumatol. 2014;32:S-85\u201395.","journal-title":"Clin Exp Rheumatol"},{"key":"1623_CR21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.autrev.2015.02.008","volume":"14","author":"F Ceccarelli","year":"2015","unstructured":"Ceccarelli F, Perricone C, Massaro L, Cipriano E, Alessandri C, Spinelli FR, et al. Assessment of disease activity in systemic lupus erythematosus: lights and shadows. Autoimmun Rev. 2015;14:601\u20138.","journal-title":"Autoimmun Rev"},{"key":"1623_CR22","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","volume":"16","author":"SA Miller","year":"1988","unstructured":"Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.","journal-title":"Nucleic Acids Res"},{"key":"1623_CR23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/sj.gene.6363923","volume":"3","author":"A Kawasaki","year":"2002","unstructured":"Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun. 2002;3:424\u20139.","journal-title":"Genes Immun"},{"key":"1623_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/0961203317717083","volume":"27","author":"A Schwarting","year":"2018","unstructured":"Schwarting A, Relle M, Meineck M, F\u00f6hr B, Triantafyllias K, Weinmann A, et al. Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men. Lupus. 2018;27:243\u201356.","journal-title":"Lupus"},{"key":"1623_CR25","doi-asserted-by":"publisher","first-page":"954292","DOI":"10.1155\/2013\/954292","volume":"2013","author":"CY Sun","year":"2013","unstructured":"Sun CY, Shen Y, Chen XW, Yan YC, Wu FX, Dai M, et al. The characteristics and significance of locally infiltrating B cells in lupus nephritis and their association with local BAFF expression. Int J Rheumatol. 2013;2013:954292.","journal-title":"Int J Rheumatol"},{"key":"1623_CR26","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.4049\/jimmunol.1600281","volume":"198","author":"S Kang","year":"2017","unstructured":"Kang S, Fedoriw Y, Brenneman EK, Truong YK, Kikly K, Vilen BJ. BAFF induces tertiary lymphoid structures and positions T cells within the glomeruli during lupus nephritis. J Immunol. 2017;198:2602\u201311.","journal-title":"J Immunol"},{"key":"1623_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12882-015-0064-y","volume":"16","author":"N Zheng","year":"2015","unstructured":"Zheng N, Wang D, Ming H, Zhang H, Yu X. BAFF promotes proliferation of human mesangial cells through interaction with BAFF-R. BMC Nephrol. 2015;16:72.","journal-title":"BMC Nephrol"},{"key":"1623_CR28","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1002\/art.23902","volume":"58","author":"S Dass","year":"2008","unstructured":"Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008;58:2993\u20139.","journal-title":"Arthritis Rheum"},{"key":"1623_CR29","doi-asserted-by":"publisher","first-page":"e000448","DOI":"10.1136\/rmdopen-2017-000448","volume":"3","author":"PA Juge","year":"2017","unstructured":"Juge PA, Gazal S, Constantin A, Mariette X, Combe B, Tebib J, et al. Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD Open. 2017;3:e000448.","journal-title":"RMD Open"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1623-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1623-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1623-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T21:01:59Z","timestamp":1605819719000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1623-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1623"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1623-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.13758\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13758\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13758\/v2","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"12 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local ethics committees of the participating centers (University Hospital Geneva, 06\u2013100; University Hospital Lausanne, 04\/07; University Hospital Bern, KEK-BE 045\/07; University Hospital Basel, EKBB 262\/06; University Hospital Essen, 12\u20135149-BO). All patients signed a written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Oliver Witzke has received research grants for clinical studies, speaker\u2019s fees, honoraria and travel expenses from Amgen, Astellas, Bristol-Myers Squibb, Chiesi, Janssen-Cilag, MSD, Novartis, Roche, Pfizer, and Sanofi. All the other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"430"}}